Ultragenyx Pharmaceutical Inc. (RARE) — Analysis Summary
Ultragenyx Pharmaceutical Inc. (RARE) has a market cap of $1.34B with year-over-year revenue growth of +20.1%. Net margin stands at -85.4%. The stock trades at a P/E ratio of -2.3.
Key Takeaways
- Revenue changed +20.1% year-over-year
- Net margin of -85.4%
- P/E ratio of -2.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, RARE posted revenue growth of +20.1% and trades at a P/E of -2.3.
Ultragenyx Pharmaceutical Inc. (RARE)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -73.6% — severe operating losses
Shareholder equity is negative, which can signal balance-sheet stress.
Net margin at -81.7% — significant losses
The latest filing shows negative free cash flow.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
1,371
Headquarters
NOVATO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.